Anti-inflammatory drugs, such as 5-aminosalicylic acid (5-ASA) or anti-TNF-α agents, such as infliximab and adalimumab, have been used in the treatment of other inflammatory conditions, such as inflammatory bowel disease (IBD). This evidence concerns the gene TNF and irritable bowel syndrome.